Teacher Retirement System of Texas Purchases 12,651 Shares of Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas raised its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 14.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 101,382 shares of the company's stock after purchasing an additional 12,651 shares during the quarter. Teacher Retirement System of Texas' holdings in Moderna were worth $4,215,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of MRNA. State Street Corp grew its stake in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after acquiring an additional 178,115 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock worth $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after acquiring an additional 178,939 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Remove Ads

Moderna Stock Performance

Shares of Moderna stock traded down $0.32 during trading hours on Tuesday, reaching $33.85. The company's stock had a trading volume of 6,937,203 shares, compared to its average volume of 6,655,472. The stock's fifty day simple moving average is $34.89 and its two-hundred day simple moving average is $45.39. The company has a market capitalization of $13.09 billion, a P/E ratio of -3.65 and a beta of 1.86. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Analyst Ratings Changes

MRNA has been the topic of several recent analyst reports. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Leerink Partners dropped their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Bank of America reduced their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Moderna has a consensus rating of "Hold" and an average price target of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.